The drugmaker filed for Chapter 11 bankruptcy protection in Delaware June 10. The court documents listed $175.1 million in assets and $262.5 million in liabilities.
The Chapter 11 protection will allow the company to keep operating while it comes up with a plan to pay the settlement.
“After conducting a thorough review of available strategic alternatives, we determined that a court-supervised sale process is the best course of action to maximize the value of our assets and address our legacy legal challenges in a fair and transparent manner,” CEO Andrew Long told Bloomberg.
Insys is the first drugamaker to file for bankruptcy protection as a result of opioid litigation.
The bankruptcy filing comes a month after Insys founder John Kapoor and four former executives were convicted in a racketeering conspiracy to bribe physicians and boost prescriptions of its fentanyl spray, Subsys.
More articles on pharmacy:
Viewpoint: The $2.1M drug price record won’t last long
Purdue Pharma hit with 4 more opioid lawsuits: 4 things to know
EpiPen shortage will drag on: 4 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.